Sun Pharmaceuticals Industries Ltd Share Price (SUNPHARMA)
₹1516.4
Sun Pharmaceuticals Industries Ltd share Performance
- ₹1506.45₹1545.55₹1516.4
0.66%
Low
Day's Volatility:2.58%
High
1.92%
- ₹922.45₹1638.85₹1516.4
39.17%
Low
52 Weeks Volatility:47.24%
High
8.08%
| Returns % | |
| 1 Month Return | -2.14 % |
| 3 Month Return | 15.11 % |
| 1 Year Return | 53.02 % |
| Market Stats | |
| Previous Close | ₹1,537.55 |
| Open | ₹1,545.55 |
| Volume | 32.67L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹3,68,909.75Cr |
Analyst Rating for Sun Pharmaceuticals Industries Ltd stock
based on 36 analysts
Based on 36 analysts offering long term price targets for Sun Pharmaceuticals Industries Ltd. An average target of ₹1553.19
Source: S&P Global Market Intelligence
Company Information
Sun Pharma's branded formulations include products for cardiovascular, central nervous system, gastroenterology, ophthalmology, and dermatology. Sun Pharma's specialty generics include injectables, inhalants, and complex products. Sun Pharma's API portfolio includes products for a range of therapeutic areas, including cardiovascular, central nervous system, gastroenterology, and dermatology.
Sun Pharma's top products include Modalert, a generic version of Modafinil for treating sleep disorders; Glocip, a generic version of Glipizide for treating diabetes; and Doxicip, a generic version of Doxycycline for treating bacterial infections. Sun Pharma's popular brands include Revital, a multivitamin supplement; Tazret, a topical retinoid for treating psoriasis; and Olmecip, a generic version of Olmesartan for treating hypertension.
Share Price: ₹1516.40 per share as on 18 Apr, 2024 04:01 PM
Market Capitalisation: ₹3,68,909.75Cr as of today
Revenue: ₹12,156.86Cr as on December 2023 (Q4 23)
Net Profit: ₹2,568.03Cr as on December 2023 (Q4 23)
Listing date: 09 Feb, 1995
| Organisation | Sun Pharmaceuticals Industries Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
What's happening
Today's Timeline - 18 Apr
11:37 AM
-Sun Pharma's Dadra facility classification as official action indicated sparks concerns over regulatory readiness, with analysts and investors holding a bearish view on the stock.
11:46 AM
-US FDA releases detailed report on six observations following inspection at Sun Pharma's Dadra plant; recent OAI classification adds to regulatory challenges faced by company.
Key events for Sun Pharmaceuticals Industries Ltd
Sun Pharma Faces Regulatory Challenges - 18 Apr, 2024
Sun Pharmaceuticals Industries Ltd faces regulatory challenges after its Dadra facility was classified as Official Action Indicated (OAI) by the US FDA. Analysts and investors hold a bearish view on the stock, which may fall up to Rs 1,330 apiece in the rest of the month.
Delhi High Court Upholds Order Against Glenmark Pharmaceuticals - 17 Apr, 2024
The Delhi High Court has upheld its order restraining Glenmark Pharmaceuticals from manufacturing, selling or advertising its asthma drug under the mark Indamet or any other deceptively similar mark to Sun Pharma's Istamet XR CP until the case is disposed of.
Sun Pharma Shares Decline on Regulatory Concerns - 15 Apr, 2024
Sun Pharma's shares decline due to USFDA issuing an OAI tag to its Mumbai unit, which may impact new launches. Analysts expect limited earnings impact but see a regulatory overhang for the drugmaker.
Sun Pharma Shares Fall After US FDA Classification - 12 Apr, 2024
Sun Pharmaceutical Industries Ltd faced a significant setback when its Dadra facility was classified as Official Action Indicated by the US Food and Drug Administration, leading to a 4% decline in share prices. The company will cooperate with regulators to achieve compliance status.
Sun Pharma's Future Looks Bright Amid Positive Forecasts - 09 Apr, 2024
Indian pharma companies are expected to see significant YoY revenue growth in Q4 FY24. Prabhudas Lilladher maintains its bullish stance on healthcare sector and has picked Sun Pharma as its top pick with a BUY rating and target price of Rs 1,640.
Sun Pharma Drops for Fifth Straight Session - 08 Apr, 2024
Sun Pharmaceuticals Industries Ltd has dropped for a fifth straight session and is quoting at Rs 1602.95, down 0.38% on the day as of 13:19 IST on the NSE. The volume in the stock stood at 5.96 lakh shares today.
Sun Pharma Appoints New CIO - 04 Apr, 2024
Sun Pharmaceuticals Industries Ltd has appointed Dheeraj Sinha as the new Executive Vice President and Chief Information Officer, effective from April 3, 2024. He replaces Anil Rao who resigned for personal reasons.
Sun Pharma Receives High Buy Calls from Analysts - 03 Apr, 2024
Sun Pharmaceutical Industries receives high optimism from analysts due to its strong standing in the global specialty space and robust outlook for its India business. The company's MD, Dilip Shanghvi, is India's richest man. Additionally, Mr. Dheeraj Sinha replaces Mr. Anil Rao as EVP and CIO.
Sun Pharma Hits 52-Week High Amid Positive Outlook - 28 Mar, 2024
Sun Pharmaceuticals Industries Ltd's stock hit a new 52-week high amid a positive outlook for its specialty portfolio. HSBC maintained a buy rating and raised the target price to Rs 1790. The filing of Nidlegy with the EU regulator and FDA approval for alopecia drug 900 deuruxolitinib are key catalysts for future growth.
Sun Pharma Founder Dilip Shanghvi's Wealth Reaches ₹1,64,300 Crore - 27 Mar, 2024
Dilip Shanghvi, the founder of Sun Pharmaceutical Industries, has a wealth of ₹1,64,300 crore. The Mumbai-based company remains a powerhouse in the pharmaceutical industry and continues to grow under his leadership.
Sun Pharma Gains on Licensing Agreement with Pharmazz - 22 Mar, 2024
Sun Pharmaceuticals Industries Ltd gains 2.46% on the NSE after licensing agreement with Pharmazz to market novel anti-stroke therapy Sovateltide as Tyvalzi in India.
Sun Pharma Sees Revival Amid Regulatory Risks - 21 Mar, 2024
According to Deepak Shenoy, Founder of Capital Mind, Sun Pharma has seen some revival and interest in the pharma space is starting to build up. However, regulatory risks from the FDA may be a concern for companies selling in the US.
Sun Pharma Receives Regulatory Approval for Winlevi Cream in Australia - 20 Mar, 2024
Sun Pharmaceuticals Industries Ltd. has received regulatory approval for its acne treatment cream, Winlevi, in Australia. The company's exclusive rights to develop and commercialize the product in several countries is expected to boost global specialty segment sales growth.
Fundamentals of Sun Pharmaceuticals Industries Ltd
Insights on Sun Pharmaceuticals Industries Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTBest in 1 Year
In the last 1 year, SUNPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 11.30K Cr → 12.63K Cr (in ₹), with an average increase of 3.6% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 16.79% to 17.07% in Dec 2023 quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, SUNPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 4 quarters, 1.98K Cr → 2.52K Cr (in ₹), with an average increase of 7.5% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 54.48% of holdings in Dec 2023 quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 9.06% to 8.92% in Dec 2023 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 13.07% to 12.93% in Dec 2023 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, SUNPHARMA stock has moved down by -2.1%
Sun Pharmaceuticals Industries Ltd Valuation
Sun Pharmaceuticals Industries Ltd in the last 5 years
Lowest (19.47x)
March 23, 2020
Today (41.44x)
April 16, 2024
Industry (60.97x)
April 16, 2024
Highest (184.63x)
August 28, 2020
Mutual Fund Holdings
| Funds | Holdings |
 ICICI Prudential Value Discovery Fund Direct Plan Growth | 6.09% |
| ICICI Prudential Bluechip Fund Direct Plan Growth | 2.69% |
| ICICI Prudential Equity & Debt Fund Direct Plan Growth | 3.9% |
 Axis Bluechip Fund Direct Plan Growth | 3.64% |
 Nippon India Pharma Fund - Direct Plan - Growth Plan | 14.91% |
Shareholding Pattern
| Investors | Holdings % | Prev. 4 periods | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.48% | 0.00 | |
| Foreign Institutions | 17.07% | 1.71 | |
| Mutual Funds | 12.93% | ||
| Retail Investors | 8.92% | ||
| Others | 6.59% |
Technicals of Sun Pharmaceuticals Industries Ltd share
News & Events of Sun Pharmaceuticals Industries Ltd
News
HC upholds its earlier order on asthma drug Indamet against Glenmark Pharma
Sun Pharma Laboratories, a wholly-owned subsidiary of Sun Pharmaceutical Industries, and Glenmark are contesting over their right to use drug names “Istamet” an... Read more
17 Apr, 2024 07:59 PMSun Pharma-FDA: Regulatory Concerns At Dadra facility Can Dent Sentiment, Say Analysts
Analysts say that the FDA action at the Dadra unit can push Sun Pharma's stock into a price-wise corrective phase.
18 Apr, 2024 11:37 AMUS FDA releases details of OAI observations at Sun Pharma’s Dadra plant
Dadra's specialization lies in the production of oral solid dosage forms and the manufacture of the blockbuster drug Revlimid, a vital revenue driver for Sun Ph... Read more
18 Apr, 2024 11:46 AMFrequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Sun Pharmaceuticals Industries Ltd shares.
Sun Pharmaceuticals Industries Ltd (SUNPHARMA) share price today is ₹1516.4
Sun Pharmaceuticals Industries Ltd is listed on NSE
Sun Pharmaceuticals Industries Ltd is listed on BSE
- Today’s highest price of Sun Pharmaceuticals Industries Ltd is ₹1545.55.
- Today’s lowest price of Sun Pharmaceuticals Industries Ltd is ₹1506.45.
PE Ratio of Sun Pharmaceuticals Industries Ltd is 41.44
PE ratio = Sun Pharmaceuticals Industries Ltd Market price per share / Sun Pharmaceuticals Industries Ltd Earnings per share
Today’s traded volume of Sun Pharmaceuticals Industries Ltd(SUNPHARMA) is 32.67L.
Today’s market capitalisation of Sun Pharmaceuticals Industries Ltd(SUNPHARMA) is ₹368909.75Cr.
| Sun Pharmaceuticals Industries Ltd(SUNPHARMA | Price |
|---|---|
52 Week High | ₹1638.85 |
52 Week Low | ₹922.45 |
Sun Pharmaceuticals Industries Ltd(SUNPHARMA) share price is ₹1516.4. It is down -7.47% from its 52 Week High price of ₹1638.85
Sun Pharmaceuticals Industries Ltd(SUNPHARMA) share price is ₹1516.4. It is up 64.39% from its 52 Week Low price of ₹922.45
| Sun Pharmaceuticals Industries Ltd(SUNPHARMA | Returns |
|---|---|
1 Day Returns | -21.15% |
1 Month Returns | -2.14% |
3 Month Returns | 15.11% |
1 Year Returns | 53.02% |